PTPRC and acute myeloid leukemia: To quantify CD45 expression on AML blasts (from 27 people with AML) that were analysed at primary diagnosis, we used erythrocytes as a negative denominator and confirmed substantial CD45 expression in all samples (Extended Data Fig. 9a).